Marine-derived drugs: Recent advances in cancer therapy and immune signaling - 17/01/21
pages | 19 |
Iconographies | 7 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Marine natural products are a prime source of novel chemical classes of anticancer agents for treating many forms of cancer. |
• | Polyphenols, polysaccharides, alkaloids, and peptides are highly active, potent, and predominant anticancer compounds. |
• | Chitosan is an excellent nanocarrier in anticancer target delivery due to hydrophilicity, biocompatibility, and biodegradability. |
• | cGAS-STING and JAK-STAT are promising immunomodulators with potential applications in cancer therapy. |
Abstract |
The marine environment is an enormous source of marine-derived natural products (MNPs), and future investigation into anticancer drug discovery. Current progress in anticancer drugs offers a rise in isolation and clinical validation of numerous innovative developments and advances in anticancer therapy. However, only a limited number of FDA-approved marine-derived anticancer drugs are available due to several challenges and limitations highlighted here. The use of chitosan in developing marine-derived drugs is promising in the nanotech sector projected for a prolific anticancer drug delivery system (DDS). The cGAS-STING-mediated immune signaling pathway is crucial, which has not been significantly investigated in anticancer therapy and needs further attention. Additionally, a small range of anticancer mediators is currently involved in regulating various JAK/STAT signaling pathways, such as immunity, cell death, and tumor formation. This review addressed critical features associated with MNPs, origin, and development of anticancer drugs. Moreover, recent advances in the nanotech delivery of anticancer drugs and understanding into cancer immunity are detailed for improved human health.
Le texte complet de cet article est disponible en PDF.Keywords : Marine-derived products, Anticancer drugs, Drug delivery system, Nanotechnology, cGAS-STING, JAK/STAT immune pathway
Plan
Vol 134
Article 111091- février 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?